Hadeel Alkofide1, Gordon S Huggins2, Robin Ruthazer3, Joni R Beshansky4, Harry P Selker5. 1. Clinical and Translational Science Graduate Program, Sackler School of Graduate Biomedical Sciences, Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA. 2. MCRI Center for Translational Genomics, Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA, USA. 3. Center for Cardiovascular Health Services Research, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA. 4. Center for Cardiovascular Health Services Research, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Regulatory and Clinical Research Management Graduate Program, Regis College, Weston, MA, USA. 5. Center for Cardiovascular Health Services Research, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA hselker@tuftsmedicalcenter.org.
Abstract
BACKGROUND: The role of adiponectin in patients with acute coronary syndromes is incompletely defined. This study investigated adiponectin levels in patients with acute coronary syndromes and the association between adiponectin and 30-day infarct size and 1-year clinical outcomes. METHODS: Retrospective analysis of 120 participants with acute coronary syndromes enrolled in the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care Trial. Blood levels were tested three times within 24 h of onset of ischaemic symptoms. Infarct size was measured at 30 days. The 1-year clinical outcome was the composite of all-cause mortality or hospitalization for heart failure. RESULTS: Using linear mixed models, log adiponectin levels decreased by -0.005 µg/mL per hour (p = 0.035). After stratifying the analysis by gender, there was no decrease in log adiponectin in men; however, levels decreased by -0.01 µg/mL per hour in women (p = 0.02). Results of multivariable regression models showed no association between log adiponectin and infarct size (β = -1.1, p = 0.64). Log adiponectin levels did not predict 1-year outcomes using Cox-proportional hazard models. CONCLUSION: There was a small decrease in plasma adiponectin shortly after symptoms of ischaemia, more noticeable in women. No relationship was found between adiponectin and infarct size or clinical outcomes. This adds to evidence showing no clear association between adiponectin and adverse outcomes in patients with acute coronary syndromes.
BACKGROUND: The role of adiponectin in patients with acute coronary syndromes is incompletely defined. This study investigated adiponectin levels in patients with acute coronary syndromes and the association between adiponectin and 30-day infarct size and 1-year clinical outcomes. METHODS: Retrospective analysis of 120 participants with acute coronary syndromes enrolled in the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care Trial. Blood levels were tested three times within 24 h of onset of ischaemic symptoms. Infarct size was measured at 30 days. The 1-year clinical outcome was the composite of all-cause mortality or hospitalization for heart failure. RESULTS: Using linear mixed models, log adiponectin levels decreased by -0.005 µg/mL per hour (p = 0.035). After stratifying the analysis by gender, there was no decrease in log adiponectin in men; however, levels decreased by -0.01 µg/mL per hour in women (p = 0.02). Results of multivariable regression models showed no association between log adiponectin and infarct size (β = -1.1, p = 0.64). Log adiponectin levels did not predict 1-year outcomes using Cox-proportional hazard models. CONCLUSION: There was a small decrease in plasma adiponectin shortly after symptoms of ischaemia, more noticeable in women. No relationship was found between adiponectin and infarct size or clinical outcomes. This adds to evidence showing no clear association between adiponectin and adverse outcomes in patients with acute coronary syndromes.
Authors: W Rathmann; B Haastert; C Herder; H Hauner; W Koenig; C Meisinger; R Holle; G Giani Journal: Int J Obes (Lond) Date: 2006-11-21 Impact factor: 5.095
Authors: Robert S Lindsay; Helaine E Resnick; Jianhui Zhu; Min L Tun; Barbara V Howard; Ying Zhang; Jeunliang Yeh; Lyle G Best Journal: Arterioscler Thromb Vasc Biol Date: 2005-03 Impact factor: 8.311
Authors: Y Okamoto; Y Arita; M Nishida; M Muraguchi; N Ouchi; M Takahashi; T Igura; Y Inui; S Kihara; T Nakamura; S Yamashita; J Miyagawa; T Funahashi; Y Matsuzawa Journal: Horm Metab Res Date: 2000-02 Impact factor: 2.936
Authors: Harry P Selker; Joni R Beshansky; Patricia R Sheehan; Joseph M Massaro; John L Griffith; Ralph B D'Agostino; Robin Ruthazer; James M Atkins; Assaad J Sayah; Michael K Levy; Michael E Richards; Tom P Aufderheide; Darren A Braude; Ronald G Pirrallo; Delanor D Doyle; Ralph J Frascone; Donald J Kosiak; James M Leaming; Carin M Van Gelder; Gert-Paul Walter; Marvin A Wayne; Robert H Woolard; Lionel H Opie; Charles E Rackley; Carl S Apstein; James E Udelson Journal: JAMA Date: 2012-03-27 Impact factor: 56.272
Authors: Donald S C Ang; Paul Welsh; Pauline Watt; Scott M Nelson; Allan Struthers; Naveed Sattar Journal: Clin Sci (Lond) Date: 2009-06-02 Impact factor: 6.124
Authors: Y Nakamura; K Shimada; D Fukuda; Y Shimada; S Ehara; M Hirose; T Kataoka; K Kamimori; S Shimodozono; Y Kobayashi; M Yoshiyama; K Takeuchi; J Yoshikawa Journal: Heart Date: 2004-05 Impact factor: 5.994
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Oleg Kornyushin; Dmitry Sonin; Alexander Polozov; Vitaly Masley; Nika Bulavinova; Maria Chervyak; Maria Istomina; Daria Mukhametdinova; Alexander Neimark; Yuri Cheburkin; Yana Toropova; Kira Derkach; Alexander Shpakov; Michael Galagudza; Evgenyi Shlyakhto Journal: Sci Rep Date: 2021-12-13 Impact factor: 4.379